Sleep in schizophrenia patients and the effects of antipsychotic drugs.
Insomnia is a common feature in schizophrenia. However, it seldom is the predominant complaint. Nevertheless, severe insomnia is often seen during exacerbations of schizophrenia, and may actually precede the appearance of other symptoms of relapse. The sleep disturbances of either never-medicated or previously treated schizophrenia patients are characterized by a sleep-onset and maintenance insomnia. In addition, stage 4 sleep, slow wave sleep (stages 3 and 4), non-REM (NREM) sleep in minutes and REM latency are decreased. The atypical antipsychotics olanzapine, risperidone, and clozapine significantly increase total sleep time and stage 2 sleep. Moreover, olanzapine and risperidone enhance slow wave sleep. On the other hand, the typical antipsychotics haloperidol, thiothixene, and flupentixol significantly reduce stage 2 sleep latency and increase sleep efficiency. Future research should address: (1) the sleep patterns in subtypes of schizophrenia patients; (2) the role of neurotransmitters other than dopamine in the disruption of sleep in schizophrenia; (3) the functional alterations in CNS areas related to the pathophysiology of schizophrenia during NREM sleep and REM sleep (brain imaging studies); (4) the short-term, intermediate-term, and long-term effects of atypical antisychotics on sleep variables.
Monti
Jaime M
JM
Department of Pharmacology and Therapeutics, Clinics Hospital, 2833/602 Zudanez Street, Montevideo 11300, Uruguay. jmonti@mednet.org.uy
Monti
Daniel
D
D014150:Antipsychotic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*; D012894:Sleep Stages / Q000502:physiology; D012893:Sleep Wake Disorders / Q000139:chemically induced*
D014150:Antipsychotic Agents